News from ampio pharmaceuticals, inc A wide array of domestic and global news stories; news topics include politics / government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle. Articles that appear in this section may be written in English or other languages, as well.

Dec 04, 2014, 08:00 ET
Ampio Pharmaceuticals Logo

Ampio Pharmaceuticals to present at the Oppenheimer Annual Healthcare Conference on December 11th, 2014

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the 25th Annual...

Dec 01, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.

Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (STRUT) Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Twenty of the Trial

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT open label portion (n=7) of the multiple injection study...

Nov 24, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.

Luoxis Announces Presentation of Multiple Studies Validating RedoxSYS as a Rapid and Non-invasive Means of Assessing Oxidative Stress

Luoxis Diagnostics, Inc., a subsidiary of Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE), today announced the presentation of three clinical and...

Nov 12, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.

Ampio updates status of clinical trials and manufacturing facility

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on its ongoing clinical trials. Dr, Vaughan Clift, Ampio's Chief...

Oct 16, 2014, 16:02 ET
Ampio Pharmaceuticals Logo.

Ampio Announces Results of the Open Label Portion of the Multiple Intra-articular Injections (MI) Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Twelve of the Trial

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced updates for the STRUT and STRIDE multiple injection studies that are proceeding...

Sep 15, 2014, 14:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Pharmaceuticals Announces Webcast for Annual Shareholder Meeting

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) a clinical trial stage biopharmaceutical company primarily focused on the development of therapies...

Sep 02, 2014, 07:56 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Update on the Phase III multicenter, double-blind STEP study of Ampion™ for Osteoarthritis of the Knee

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced an update on the phase III, multicenter, double-blind STEP study of Ampion™...

Aug 25, 2014, 07:56 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Letter to the Ampio Shareholders in Regard to the STEP Study and Ampio's plans for the Ampion™ BLA

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today is issuing this response to the most commonly asked questions in regards to the STEP study...

Aug 21, 2014, 07:56 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio reports that due to temperature deviations below product specifications during shipments to the Ampion™ STEP Study clinical sites, release of data will be delayed

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a delay in the data analysis of the STEP Study due to the discovery by the...

Aug 20, 2014, 07:56 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Analysis Of Available Data From Optimeyes Study (Blinded And Open Label) Of Optina™ For The Treatment Of Diabetic Macular Edema (DME) Indicates Potential For Significant Clinical Benefit

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that in response to requests from patients and physicians, the company has...

Aug 18, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Announces Very Positive Results of the Open Label Portion of the Multiple Intra-articular Injections Study of Ampion™ in Patients with Osteoarthritis of the Knee at Week Six of the Trial

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the 6 weeks results of the open label portion of the multiple injections of...

Aug 11, 2014, 08:00 ET
Luoxis Diagnostics Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Luoxis Broadens Global Research Network for RedoxSYS™ ORP (oxidation-reduction potential) diagnostic system; Announces 17 Studies Currently Underway and Additional 30 Studies Set to Begin in 2014

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that subsidiary Luoxis Diagnostics has expanded its academic and pharmaceutical...

Aug 05, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio announces positive results on the open label portion of the Multiple injection Study of Ampion™ in patients with osteoarthritis of the knee.

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the one month results of the open label portion of the multiple injections of...

Jul 30, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Pharmaceuticals announces the FDA has issued a written response and accepted the Ampio plan for beginning production of Ampion™ in the new facility.

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced a positive written response from the FDA in regards to the company's plans to begin...

Jul 23, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Pharmaceuticals announces the opening of its new headquarters, manufacturing and research facility in Englewood Colorado

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the opening of its new headquarters, manufacturing and research facility: Ampio...

Jun 30, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Initiates Study of Multiple Injections of Ampion™ Into the Knees of Patients with OA of the Knee to Assess its Healing and Cartilage Regeneration Effects

Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has started patient enrollment for the MULTIPLE INJECTIONS STUDY using...

Jun 25, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Pharmaceuticals, in Response to Positive Feedback, Closes Enrollment in the OptimEyes Study (Optina™) and Will Present the Data to the FDA for Guidance

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that it has informed the Transplant and Ophthalmology Division of the FDA of its...

Jun 05, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Pharmaceuticals Announces Appointment of Gregory A. Gould as Chief Financial Officer

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced the appointment of Gregory A. Gould as Chief Financial Officer, Treasurer, and...

May 21, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Pharmaceuticals to present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3rd at 8:30 AM

 Ampio Pharmaceuticals, Inc. (NYSE MKT: AMPE) today announced that the company is scheduled to present a corporate update at the Jefferies...

Apr 21, 2014, 08:00 ET
Ampio Pharmaceuticals Logo.  (PRNewsFoto/Ampio Pharmaceuticals, Inc.)

Ampio Pharmaceuticals' Vyrix Files Registration Statement for Proposed Initial Public Offering

 Ampio Pharmaceuticals Inc. (NYSE MKT: AMPE) today announced that its wholly-owned subsidiary Vyrix Pharmaceuticals has filed a registration...